{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T06:39:12Z","timestamp":1773297552147,"version":"3.50.1"},"publisher-location":"New York, NY","reference-count":56,"publisher":"Springer New York","isbn-type":[{"value":"9781493991693","type":"print"},{"value":"9781493991709","type":"electronic"}],"license":[{"start":{"date-parts":[[2019,1,1]],"date-time":"2019-01-01T00:00:00Z","timestamp":1546300800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2019]]},"DOI":"10.1007\/978-1-4939-9170-9_18","type":"book-chapter","created":{"date-parts":[[2019,3,25]],"date-time":"2019-03-25T13:03:05Z","timestamp":1553518985000},"page":"293-306","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Toward In Vivo Gene Therapy Using CRISPR"],"prefix":"10.1007","author":[{"given":"Kristian Alsbjerg","family":"Skipper","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jacob Giehm","family":"Mikkelsen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2019,3,26]]},"reference":[{"key":"18_CR1","doi-asserted-by":"publisher","DOI":"10.7554\/eLife.27873","volume":"6","author":"RO Bak","year":"2017","unstructured":"Bak RO, Dever DP, Reinisch A, Cruz Hernandez D, Majeti R, Porteus MH (2017) Multiplexed genetic engineering of human hematopoietic stem and progenitor cells using CRISPR\/Cas9 and AAV6. Elife 6:e27873","journal-title":"Elife"},{"key":"18_CR2","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1038\/nature20134","volume":"539","author":"DP Dever","year":"2016","unstructured":"Dever DP, Bak RO, Reinisch A, Camarena J, Washington G, Nicolas CE, Pavel-Dinu M, Saxena N, Wilkens AB, Mantri S et al (2016) CRISPR\/Cas9 beta-globin gene targeting in human haematopoietic stem cells. Nature 539:384\u2013389","journal-title":"Nature"},{"key":"18_CR3","doi-asserted-by":"publisher","first-page":"360ra134","DOI":"10.1126\/scitranslmed.aaf9336","volume":"8","author":"MA DeWitt","year":"2016","unstructured":"DeWitt MA, Magis W, Bray NL, Wang T, Berman JR, Urbinati F, Heo SJ, Mitros T, Munoz DP, Boffelli D et al (2016) Selection-free genome editing of the sickle mutation in human adult hematopoietic stem\/progenitor cells. Sci Transl Med 8:360ra134","journal-title":"Sci Transl Med"},{"key":"18_CR4","doi-asserted-by":"publisher","first-page":"1298","DOI":"10.1038\/nbt1353","volume":"25","author":"A Lombardo","year":"2007","unstructured":"Lombardo A, Genovese P, Beausejour CM, Colleoni S, Lee YL, Kim KA, Ando D, Urnov FD, Galli C, Gregory PD et al (2007) Gene editing in human stem cells using zinc finger nucleases and integrase-defective lentiviral vector delivery. Nat Biotechnol 25:1298\u20131306","journal-title":"Nat Biotechnol"},{"key":"18_CR5","doi-asserted-by":"publisher","DOI":"10.7554\/eLife.12213","volume":"5","author":"Y Cai","year":"2016","unstructured":"Cai Y, Laustsen A, Zhou Y, Sun C, Anderson MV, Li S, Uldbjerg N, Luo Y, Jakobsen MR, Mikkelsen JG (2016) Targeted, homology-driven gene insertion in stem cells by ZFN-loaded \u2018all-in-one\u2019 lentiviral vectors. Elife 5:e12213","journal-title":"Elife"},{"key":"18_CR6","doi-asserted-by":"publisher","first-page":"1256","DOI":"10.1038\/nbt.3408","volume":"33","author":"J Wang","year":"2015","unstructured":"Wang J, Exline CM, DeClercq JJ, Llewellyn GN, Hayward SB, Li PW, Shivak DA, Surosky RT, Gregory PD, Holmes MC et al (2015) Homology-driven genome editing in hematopoietic stem and progenitor cells using ZFN mRNA and AAV6 donors. Nat Biotechnol 33:1256\u20131263","journal-title":"Nat Biotechnol"},{"key":"18_CR7","doi-asserted-by":"publisher","first-page":"2215","DOI":"10.1056\/NEJMoa1708538","volume":"377","author":"LA George","year":"2017","unstructured":"George LA, Sullivan SK, Giermasz A, Rasko JEJ, Samelson-Jones BJ, Ducore J, Cuker A, Sullivan LM, Majumdar S, Teitel J et al (2017) Hemophilia B gene therapy with a high-specific-activity factor IX variant. N Engl J Med 377:2215\u20132227","journal-title":"N Engl J Med"},{"key":"18_CR8","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1038\/nbt.2884","volume":"32","author":"H Yin","year":"2014","unstructured":"Yin H, Xue W, Chen S, Bogorad RL, Benedetti E, Grompe M, Koteliansky V, Sharp PA, Jacks T, Anderson DG (2014) Genome editing with Cas9 in adult mice corrects a disease mutation and phenotype. Nat Biotechnol 32:551\u2013553","journal-title":"Nat Biotechnol"},{"key":"18_CR9","doi-asserted-by":"publisher","first-page":"3954","DOI":"10.1016\/j.febslet.2014.09.008","volume":"588","author":"R Cheng","year":"2014","unstructured":"Cheng R, Peng J, Yan Y, Cao P, Wang J, Qiu C, Tang L, Liu D, Tang L, Jin J et al (2014) Efficient gene editing in adult mouse livers via adenoviral delivery of CRISPR\/Cas9. FEBS Lett 588:3954\u20133958","journal-title":"FEBS Lett"},{"key":"18_CR10","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1161\/CIRCRESAHA.115.304351","volume":"115","author":"Q Ding","year":"2014","unstructured":"Ding Q, Strong A, Patel KM, Ng SL, Gosis BS, Regan SN, Cowan CA, Rader DJ, Musunuru K (2014) Permanent alteration of PCSK9 with in vivo CRISPR-Cas9 genome editing. Circ Res 115:488\u2013492","journal-title":"Circ Res"},{"key":"18_CR11","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1089\/hum.2015.087","volume":"26","author":"D Wang","year":"2015","unstructured":"Wang D, Mou H, Li S, Li Y, Hough S, Tran K, Li J, Yin H, Anderson DG, Sontheimer EJ et al (2015) Adenovirus-mediated somatic genome editing of Pten by CRISPR\/Cas9 in mouse liver in spite of Cas9-specific immune responses. Hum Gene Ther 26:432\u2013442","journal-title":"Hum Gene Ther"},{"issue":"7546","key":"18_CR12","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1038\/nature14299","volume":"520","author":"FA Ran","year":"2015","unstructured":"Ran FA, Cong L, Yan WX, Scott DA, Gootenberg JS, Kriz AJ, Zetsche B, Shalem O, Wu X, Makarova KS et al (2015) In vivo genome editing using Staphylococcus aureus Cas9. Nature 520(7546):186\u2013191","journal-title":"Nature"},{"key":"18_CR13","doi-asserted-by":"publisher","first-page":"1674","DOI":"10.1038\/s41467-018-04048-4","volume":"9","author":"PI Thakore","year":"2018","unstructured":"Thakore PI, Kwon JB, Nelson CE, Rouse DC, Gemberling MP, Oliver ML, Gersbach CA (2018) RNA-guided transcriptional silencing in vivo with S. aureus CRISPR-Cas9 repressors. Nat Commun 9:1674","journal-title":"Nat Commun"},{"key":"18_CR14","doi-asserted-by":"publisher","DOI":"10.1038\/srep44624","volume":"7","author":"KE Jarrett","year":"2017","unstructured":"Jarrett KE, Lee CM, Yeh YH, Hsu RH, Gupta R, Zhang M, Rodriguez PJ, Lee CS, Gillard BK, Bissig KD et al (2017) Sci Rep 7:44624","journal-title":"Sci Rep"},{"key":"18_CR15","doi-asserted-by":"publisher","first-page":"1655","DOI":"10.1073\/pnas.1617726114","volume":"114","author":"R Calcedo","year":"2017","unstructured":"Calcedo R, Somanathan S, Qin Q, Betts MR, Rech AJ, Vonderheide RH, Mueller C, Flotte TR, Wilson JM (2017) Class I-restricted T-cell responses to a polymorphic peptide in a gene therapy clinical trial for alpha-1-antitrypsin deficiency. Proc Natl Acad Sci U S A 114:1655\u20131659","journal-title":"Proc Natl Acad Sci U S A"},{"key":"18_CR16","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1089\/humc.2013.168","volume":"24","author":"MJ Chiuchiolo","year":"2013","unstructured":"Chiuchiolo MJ, Kaminsky SM, Sondhi D, Hackett NR, Rosenberg JB, Frenk EZ, Hwang Y, Van de Graaf BG, Hutt JA, Wang G et al (2013) Intrapleural administration of an AAVrh.10 vector coding for human alpha1-antitrypsin for the treatment of alpha1-antitrypsin deficiency. Hum Gene Ther Clin Dev 24:161\u2013173","journal-title":"Hum Gene Ther Clin Dev"},{"key":"18_CR17","doi-asserted-by":"publisher","first-page":"1239","DOI":"10.1089\/hum.2011.053","volume":"22","author":"TR Flotte","year":"2011","unstructured":"Flotte TR, Trapnell BC, Humphries M, Carey B, Calcedo R, Rouhani F, Campbell-Thompson M, Yachnis AT, Sandhaus RA, McElvaney NG et al (2011) Phase 2 clinical trial of a recombinant adeno-associated viral vector expressing alpha1-antitrypsin: interim results. Hum Gene Ther 22:1239\u20131247","journal-title":"Hum Gene Ther"},{"key":"18_CR18","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1007\/978-1-4939-7163-3_27","volume":"1639","author":"AM Gruntman","year":"2017","unstructured":"Gruntman AM, Flotte TR (2017) Therapeutics: gene therapy for alpha-1 antitrypsin deficiency. Methods Mol Biol 1639:267\u2013275","journal-title":"Methods Mol Biol"},{"key":"18_CR19","doi-asserted-by":"publisher","first-page":"1387","DOI":"10.1016\/j.ymthe.2017.03.029","volume":"25","author":"C Mueller","year":"2017","unstructured":"Mueller C, Gernoux G, Gruntman AM, Borel F, Reeves EP, Calcedo R, Rouhani FN, Yachnis A, Humphries M, Campbell-Thompson M et al (2017) 5 Year expression and neutrophil defect repair after gene therapy in alpha-1 antitrypsin deficiency. Mol Ther 25:1387\u20131394","journal-title":"Mol Ther"},{"issue":"8","key":"18_CR20","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1089\/hum.2017.227","volume":"29","author":"S Shen","year":"2018","unstructured":"Shen S, Sanchez ME, Blomenkamp K, Corcoran EM, Marco E, Yudkoff CJ, Jiang H, Teckman JH, Bumcrot D, Albright CF (2018) Amelioration of alpha-1 antitrypsin deficiency diseases with genome editing in transgenic mice. Hum Gene Ther 29(8):861\u2013873","journal-title":"Hum Gene Ther"},{"issue":"8","key":"18_CR21","doi-asserted-by":"publisher","first-page":"853","DOI":"10.1089\/hum.2017.225","volume":"29","author":"CQ Song","year":"2018","unstructured":"Song CQ, Wang D, Jiang T, O\u2019Connor K, Tang Q, Cai L, Li X, Weng Z, Yin H, Gao G et al (2018) In vivo genome editing partially restores alpha1-antitrypsin in a murine model of AAT deficiency. Hum Gene Ther 29(8):853\u2013860","journal-title":"Hum Gene Ther"},{"key":"18_CR22","doi-asserted-by":"publisher","first-page":"1241","DOI":"10.1016\/j.ymthe.2018.02.023","volume":"26","author":"K Singh","year":"2018","unstructured":"Singh K, Evens H, Nair N, Rincon MY, Sarcar S, Samara-Kuko E, Chuah MK, VandenDriessche T (2018) Efficient in vivo liver-directed gene editing using CRISPR\/Cas9. Mol Ther 26:1241\u20131254","journal-title":"Mol Ther"},{"key":"18_CR23","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms15334","volume":"8","author":"G Petris","year":"2017","unstructured":"Petris G, Casini A, Montagna C, Lorenzin F, Prandi D, Romanel A, Zasso J, Conti L, Demichelis F, Cereseto A (2017) Hit and go CAS9 delivered through a lentiviral based self-limiting circuit. Nat Commun 8:15334","journal-title":"Nat Commun"},{"key":"18_CR24","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1016\/j.ymthe.2016.12.006","volume":"25","author":"GX Ruan","year":"2017","unstructured":"Ruan GX, Barry E, Yu D, Lukason M, Cheng SH, Scaria A (2017) CRISPR\/Cas9-mediated genome editing as a therapeutic approach for leber congenital amaurosis 10. Mol Ther 25:331\u2013341","journal-title":"Mol Ther"},{"key":"18_CR25","doi-asserted-by":"publisher","first-page":"2980","DOI":"10.1016\/j.celrep.2017.08.075","volume":"20","author":"N Merienne","year":"2017","unstructured":"Merienne N, Vachey G, de Longprez L, Meunier C, Zimmer V, Perriard G, Canales M, Mathias A, Herrgott L, Beltraminelli T et al (2017) The self-inactivating KamiCas9 system for the editing of CNS disease genes. Cell Rep 20:2980\u20132991","journal-title":"Cell Rep"},{"key":"18_CR26","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1126\/science.aad5143","volume":"351","author":"CE Nelson","year":"2016","unstructured":"Nelson CE, Hakim CH, Ousterout DG, Thakore PI, Moreb EA, Castellanos Rivera RM, Madhavan S, Pan X, Ran FA, Yan WX et al (2016) In vivo genome editing improves muscle function in a mouse model of Duchenne muscular dystrophy. Science 351:403\u2013407","journal-title":"Science"},{"key":"18_CR27","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1126\/science.aad5177","volume":"351","author":"M Tabebordbar","year":"2016","unstructured":"Tabebordbar M, Zhu K, Cheng JK, Chew WL, Widrick JJ, Yan WX, Maesner C, Wu EY, Xiao R, Ran FA et al (2016) In vivo gene editing in dystrophic mouse muscle and muscle stem cells. Science 351:407\u2013411","journal-title":"Science"},{"key":"18_CR28","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1126\/science.aad5725","volume":"351","author":"C Long","year":"2016","unstructured":"Long C, Amoasii L, Mireault AA, McAnally JR, Li H, Sanchez-Ortiz E, Bhattacharyya S, Shelton JM, Bassel-Duby R, Olson EN (2016) Postnatal genome editing partially restores dystrophin expression in a mouse model of muscular dystrophy. Science 351:400\u2013403","journal-title":"Science"},{"key":"18_CR29","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms14454","volume":"8","author":"NE Bengtsson","year":"2017","unstructured":"Bengtsson NE, Hall JK, Odom GL, Phelps MP, Andrus CR, Hawkins RD, Hauschka SD, Chamberlain JR, Chamberlain JS (2017) Muscle-specific CRISPR\/Cas9 dystrophin gene editing ameliorates pathophysiology in a mouse model for Duchenne muscular dystrophy. Nat Commun 8:14454","journal-title":"Nat Commun"},{"issue":"418","key":"18_CR30","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aan8081","volume":"9","author":"L Amoasii","year":"2017","unstructured":"Amoasii L, Long C, Li H, Mireault AA, Shelton JM, Sanchez-Ortiz E, McAnally JR, Bhattacharyya S, Schmidt F, Grimm D et al (2017) Single-cut genome editing restores dystrophin expression in a new mouse model of muscular dystrophy. Sci Transl Med 9(418):eaan8081","journal-title":"Sci Transl Med"},{"key":"18_CR31","doi-asserted-by":"publisher","first-page":"1495","DOI":"10.1016\/j.cell.2017.10.025","volume":"171","author":"HK Liao","year":"2017","unstructured":"Liao HK, Hatanaka F, Araoka T, Reddy P, Wu MZ, Sui Y, Yamauchi T, Sakurai M, O\u2019Keefe DD, Nunez-Delicado E et al (2017) In vivo target gene activation via CRISPR\/Cas9-mediated trans-epigenetic modulation. Cell 171:1495\u20131507. e1415","journal-title":"Cell"},{"key":"18_CR32","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1038\/nature14136","volume":"517","author":"S Konermann","year":"2015","unstructured":"Konermann S, Brigham MD, Trevino AE, Joung J, Abudayyeh OO, Barcena C, Hsu PD, Habib N, Gootenberg JS, Nishimasu H et al (2015) Genome-scale transcriptional activation by an engineered CRISPR-Cas9 complex. Nature 517:583\u2013588","journal-title":"Nature"},{"key":"18_CR33","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1038\/mt.2015.220","volume":"24","author":"B Bakondi","year":"2016","unstructured":"Bakondi B, Lv W, Lu B, Jones MK, Tsai Y, Kim KJ, Levy R, Akhtar AA, Breunig JJ, Svendsen CN et al (2016) In vivo CRISPR\/Cas9 gene editing corrects retinal dystrophy in the S334ter-3 rat model of autosomal dominant retinitis pigmentosa. Mol Ther 24:556\u2013563","journal-title":"Mol Ther"},{"key":"18_CR34","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1093\/hmg\/ddx438","volume":"27","author":"SG Giannelli","year":"2018","unstructured":"Giannelli SG, Luoni M, Castoldi V, Massimino L, Cabassi T, Angeloni D, Demontis GC, Leocani L, Andreazzoli M, Broccoli V (2018) Cas9\/sgRNA selective targeting of the P23H Rhodopsin mutant allele for treating retinitis pigmentosa by intravitreal AAV9.PHP.B-based delivery. Hum Mol Genet 27:761\u2013779","journal-title":"Hum Mol Genet"},{"key":"18_CR35","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1089\/crispr.2017.0009","volume":"1","author":"P Li","year":"2018","unstructured":"Li P, Kleinstiver BP, Leon MY, Prew MS, Navarro-Gomez D, Greenwald SH, Pierce EA, Keith Joung J, Liu Q (2018) Allele-specific CRISPR-Cas9 genome editing of the single-base P23H mutation for rhodopsin-associated dominant retinitis pigmentosa. CRISPR J 1:55\u201364","journal-title":"CRISPR J"},{"key":"18_CR36","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms14716","volume":"8","author":"W Yu","year":"2017","unstructured":"Yu W, Mookherjee S, Chaitankar V, Hiriyanna S, Kim JW, Brooks M, Ataeijannati Y, Sun X, Dong L, Li T et al (2017) Nrl knockdown by AAV-delivered CRISPR\/Cas9 prevents retinal degeneration in mice. Nat Commun 8:14716","journal-title":"Nat Commun"},{"issue":"7","key":"18_CR37","doi-asserted-by":"publisher","first-page":"1818","DOI":"10.1016\/j.ymthe.2018.04.017","volume":"26","author":"AM Moreno","year":"2018","unstructured":"Moreno AM, Fu X, Zhu J, Katrekar D, Shih YV, Marlett J, Cabotaje J, Tat J, Naughton J, Lisowski L et al (2018) In situ gene therapy via AAV-CRISPR-Cas9-mediated targeted gene regulation. Mol Ther 26(7):1818\u20131827","journal-title":"Mol Ther"},{"key":"18_CR38","doi-asserted-by":"publisher","first-page":"e389","DOI":"10.1038\/mtna.2016.92","volume":"5","author":"MC Latella","year":"2016","unstructured":"Latella MC, Di Salvo MT, Cocchiarella F, Benati D, Grisendi G, Comitato A, Marigo V, Recchia A (2016) In vivo editing of the human mutant rhodopsin gene by electroporation of plasmid-based CRISPR\/Cas9 in the mouse retina. Mol Ther Nucleic Acids 5:e389","journal-title":"Mol Ther Nucleic Acids"},{"key":"18_CR39","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1038\/s41467-017-00140-3","volume":"8","author":"X Huang","year":"2017","unstructured":"Huang X, Zhou G, Wu W, Duan Y, Ma G, Song J, Xiao R, Vandenberghe L, Zhang F, D\u2019Amore PA et al (2017) Genome editing abrogates angiogenesis in vivo. Nat Commun 8:112","journal-title":"Nat Commun"},{"key":"18_CR40","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1101\/gr.219089.116","volume":"27","author":"K Kim","year":"2017","unstructured":"Kim K, Park SW, Kim JH, Lee SH, Kim D, Koo T, Kim KE, Kim JH, Kim JS (2017) Genome surgery using Cas9 ribonucleoproteins for the treatment of age-related macular degeneration. Genome Res 27:419\u2013426","journal-title":"Genome Res"},{"key":"18_CR41","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/j.omtn.2017.08.016","volume":"9","author":"A Holmgaard","year":"2017","unstructured":"Holmgaard A, Askou AL, Benckendorff JNE, Thomsen EA, Cai Y, Bek T, Mikkelsen JG, Corydon TJ (2017) In vivo knockout of the Vegfa Gene by lentiviral delivery of CRISPR\/Cas9 in mouse retinal pigment epithelium cells. Mol Ther Nucleic Acids 9:89\u201399","journal-title":"Mol Ther Nucleic Acids"},{"key":"18_CR42","doi-asserted-by":"publisher","first-page":"11199","DOI":"10.1073\/pnas.1706193114","volume":"114","author":"A Jain","year":"2017","unstructured":"Jain A, Zode G, Kasetti RB, Ran FA, Yan W, Sharma TP, Bugge K, Searby CC, Fingert JH, Zhang F et al (2017) CRISPR-Cas9-based treatment of myocilin-associated glaucoma. Proc Natl Acad Sci U S A 114:11199\u201311204","journal-title":"Proc Natl Acad Sci U S A"},{"key":"18_CR43","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms14500","volume":"8","author":"E Kim","year":"2017","unstructured":"Kim E, Koo T, Park SW, Kim D, Kim K, Cho HY, Song DW, Lee KJ, Jung MH, Kim S et al (2017) In vivo genome editing with a small Cas9 orthologue derived from Campylobacter jejuni. Nat Commun 8:14500","journal-title":"Nat Commun"},{"key":"18_CR44","doi-asserted-by":"publisher","first-page":"1732","DOI":"10.1073\/pnas.1214387110","volume":"110","author":"CL Montana","year":"2013","unstructured":"Montana CL, Kolesnikov AV, Shen SQ, Myers CA, Kefalov VJ, Corbo JC (2013) Reprogramming of adult rod photoreceptors prevents retinal degeneration. Proc Natl Acad Sci U S A 110:1732\u20131737","journal-title":"Proc Natl Acad Sci U S A"},{"key":"18_CR45","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1038\/nbt.3081","volume":"33","author":"JA Zuris","year":"2015","unstructured":"Zuris JA, Thompson DB, Shu Y, Guilinger JP, Bessen JL, Hu JH, Maeder ML, Joung JK, Chen ZY, Liu DR (2015) Cationic lipid-mediated delivery of proteins enables efficient protein-based genome editing in vitro and in vivo. Nat Biotechnol 33:73\u201380","journal-title":"Nat Biotechnol"},{"key":"18_CR46","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1038\/nature25164","volume":"553","author":"X Gao","year":"2018","unstructured":"Gao X, Tao Y, Lamas V, Huang M, Yeh WH, Pan B, Hu YJ, Hu JH, Thompson DB, Shu Y et al (2018) Treatment of autosomal dominant hearing loss by in vivo delivery of genome editing agents. Nature 553:217\u2013221","journal-title":"Nature"},{"key":"18_CR47","doi-asserted-by":"publisher","first-page":"868","DOI":"10.1038\/nmeth.3993","volume":"13","author":"WL Chew","year":"2016","unstructured":"Chew WL, Tabebordbar M, Cheng JK, Mali P, Wu EY, Ng AH, Zhu K, Wagers AJ, Church GM (2016) A multifunctional AAV-CRISPR-Cas9 and its host response. Nat Methods 13:868\u2013874","journal-title":"Nat Methods"},{"key":"18_CR48","doi-asserted-by":"publisher","first-page":"1657","DOI":"10.4049\/jimmunol.1500804","volume":"195","author":"R Mortensen","year":"2015","unstructured":"Mortensen R, Nissen TN, Blauenfeldt T, Christensen JP, Andersen P, Dietrich J (2015) Adaptive immunity against Streptococcus pyogenes in adults involves increased IFN-gamma and IgG3 responses compared with children. J Immunol 195:1657\u20131664","journal-title":"J Immunol"},{"key":"18_CR49","doi-asserted-by":"publisher","first-page":"1117","DOI":"10.1128\/CVI.00506-09","volume":"17","author":"P Colque-Navarro","year":"2010","unstructured":"Colque-Navarro P, Jacobsson G, Andersson R, Flock JI, Mollby R (2010) Levels of antibody against 11 Staphylococcus aureus antigens in a healthy population. Clin Vaccine Immunol 17:1117\u20131123","journal-title":"Clin Vaccine Immunol"},{"key":"18_CR50","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1128\/CDLI.12.3.387-398.2005","volume":"12","author":"A Dryla","year":"2005","unstructured":"Dryla A, Prustomersky S, Gelbmann D, Hanner M, Bettinger E, Kocsis B, Kustos T, Henics T, Meinke A, Nagy E (2005) Comparison of antibody repertoires against Staphylococcus aureus in healthy individuals and in acutely infected patients. Clin Diagn Lab Immunol 12:387\u2013398","journal-title":"Clin Diagn Lab Immunol"},{"key":"18_CR51","doi-asserted-by":"crossref","unstructured":"Charlesworth CT, Deshpande PS, Dever DP, Dejene B, Gomez-Ospina N, Mantri S, Pavel-Dinu M, Camarena J, Weinberg KI, Porteus MH (2018) Identification of pre-existing adaptive immunity to Cas9 proteins in humans. BioRxiv. https:\/\/doi.org\/10.1101\/243345","DOI":"10.1101\/243345"},{"key":"18_CR52","doi-asserted-by":"publisher","first-page":"166ra161","DOI":"10.1126\/scitranslmed.3004853","volume":"5","author":"RH Al-Mashhadi","year":"2013","unstructured":"Al-Mashhadi RH, Sorensen CB, Kragh PM, Christoffersen C, Mortensen MB, Tolbod LP, Thim T, Du Y, Li J, Liu Y et al (2013) Familial hypercholesterolemia and atherosclerosis in cloned minipigs created by DNA transposition of a human PCSK9 gain-of-function mutant. Sci Transl Med 5:166ra161","journal-title":"Sci Transl Med"},{"key":"18_CR53","doi-asserted-by":"publisher","DOI":"10.7554\/eLife.01911","volume":"3","author":"Y Cai","year":"2014","unstructured":"Cai Y, Bak RO, Mikkelsen JG (2014) Targeted genome editing by lentiviral protein transduction of zinc-finger and TAL-effector nucleases. Elife 3:e01911","journal-title":"Elife"},{"key":"18_CR54","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1038\/gt.2016.27","volume":"23","author":"JG Choi","year":"2016","unstructured":"Choi JG, Dang Y, Abraham S, Ma H, Zhang J, Guo H, Cai Y, Mikkelsen JG, Wu H, Shankar P et al (2016) Lentivirus pre-packed with Cas9 protein for safer gene editing. Gene Ther 23:627\u2013633","journal-title":"Gene Ther"},{"key":"18_CR55","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1016\/j.omtn.2018.02.006","volume":"11","author":"KA Skipper","year":"2018","unstructured":"Skipper KA, Nielsen MG, Andersen S, Ryo LB, Bak RO, Mikkelsen JG (2018) Time-restricted PiggyBac DNA transposition by transposase protein delivery using lentivirus-derived nanoparticles. Mol Ther Nucleic Acids 11:253\u2013262","journal-title":"Mol Ther Nucleic Acids"},{"key":"18_CR56","doi-asserted-by":"publisher","first-page":"1179","DOI":"10.1038\/nbt.4005","volume":"35","author":"H Yin","year":"2017","unstructured":"Yin H, Song CQ, Suresh S, Wu Q, Walsh S, Rhym LH, Mintzer E, Bolukbasi MF, Zhu LJ, Kauffman K et al (2017) Structure-guided chemical modification of guide RNA enables potent non-viral in vivo genome editing. Nat Biotechnol 35:1179\u20131187","journal-title":"Nat Biotechnol"}],"container-title":["Methods in Molecular Biology","CRISPR Gene Editing"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/978-1-4939-9170-9_18","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,12,3]],"date-time":"2020-12-03T12:57:20Z","timestamp":1607000240000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/978-1-4939-9170-9_18"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019]]},"ISBN":["9781493991693","9781493991709"],"references-count":56,"URL":"https:\/\/doi.org\/10.1007\/978-1-4939-9170-9_18","relation":{},"ISSN":["1064-3745","1940-6029"],"issn-type":[{"value":"1064-3745","type":"print"},{"value":"1940-6029","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019]]},"assertion":[{"value":"26 March 2019","order":1,"name":"first_online","label":"First Online","group":{"name":"ChapterHistory","label":"Chapter History"}}]}}